EOLS Q3 2024 Earnings — Evolus, Inc. Revenue & Financial Results | Market Cap Arena

EOLSEvolus, Inc.

$353M

Q3 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$61M+22.1% YoY

Gross Profit

$43M70.2% margin

Operating Income

-$15M-25.3% margin

Net Income

-$19M-31.4% margin

EPS (Diluted)

$-0.30

QoQ Revenue Growth

-8.7%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$7M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$230M

Total Liabilities

$224M

Stockholders' Equity

$6M

Cash & Equivalents

$85M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$61M	$50M	+22.1%
Gross Profit	$43M	$35M	+23.9%
Operating Income	-$15M	-$13M	-15.1%
Net Income	-$19M	-$17M	-13.3%

Revenue Segments

Product

$60M98%

Service

$921,0002%